🔴 Veradermics is trading 5% down today as investors digest gains from positive Phase 2 trial results

Veradermics is trading at $117.48 (5% down) as the stock gives back a portion of yesterday's gains following a sharp rally triggered by positive Phase 2 trial results for its oral hair loss drug, VDPHL01, in females.

• The pullback follows significant enthusiasm regarding VDPHL01’s potential as a first-in-class FDA-approved treatment for hair loss.
• Investors are currently processing the recent surge alongside existing data from the drug's male Phase 2/3 clinical trials.